Webmaster

On 2 June 2026, China's National Medical Products Administration (NMPA) released a draft proposal for public consultation that would grant priority review status to certain active pharmaceutical ingredients (APIs). The draft proposal outlines three circumstances under which an API may qualify for priority review: APIs used in urgently needed medicines included on China's drug shortage lists, or otherwise deemed critical to public health. The first domestic registration of an API developed as...

MAAB Group is pleased to announce its strategic partnership with The Reflux Company , alongside participation in its recently completed oversubscribed seed funding round. This collaboration marks an important milestone in MAAB’s continued expansion into innovative global healthcare technologies, and represents our first strategic engagement in the United States . A Unified Platform for Reflux Care The Reflux Company is building a unique global platform focused exclusively on the diagnosis and...

In February 2026, China’s National Healthcare Security Administration (NHSA) introduced the Measures for Pre-Communication on Reference Drugs (Interim) . While technical in nature, the policy represents an interesting initiative within China’s evolving pharmacoeconomic framework and may have practical implications for companies preparing for reimbursement discussions. At its core, the new mechanism allows pharmaceutical companies to communicate with the NHSA in advance to determine the...